This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Windtree Therapeutics, Inc.
Drug Names(s): lucinactant
Description: Surfaxin is a synthetic, peptide-containing, precision-engineered liquid instillate surfactant formulation that contains sinapultide (KL4), a novel 21-amino acid peptide designed to mimic the function of the critical human surfactant protein, SP-B. Surfaxin is completely synthetic and thus avoids any potential risks associated with therapies derived from animal origin. Surfaxin-LS is a lyophilized formulation of Surfaxin.
Deal Structure: In 2006, Discovery Laboratories licensed Surfaxin for RDS to Esteve, S.A. in Spain and Domp S.p.A. in Italy to commericalize the drug in their respective countries.
In December 2010, Discovery Laboratories and Genzyme Pharmaceuticals entered into a Supply Agreement. Pursuant to the Supply Agreement, Genzyme will provide the Company with Palmitoyl-oleyl phosphatidylglycerol (POPG) Na LP-04-180, a necessary ingredient essential to produce Discovery's synthetic, peptide-containing pulmonary surfactant (lucinactant) in liquid, lyophilized or other dosage forms and including, without limitation, the branded drug product candidates Surfaxin, Surfaxin LST, and Aerosurf.
Partners: Esteve, S.A. Dompé S.p.A.
Pink Sheet For Discovery’s Surfaxin, Another Delay
Pink Sheet Discovery Labs Surfaxin update
Additional information available to subscribers only: